Bright Peak Therapeutics Announces $107 Million Series B globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Proceeds to advance company's pipeline of next-generation cytokine immunotherapies Laura Shawver, Christine Siu join as independent directors BASEL, Switzerland and SAN DIEGO, Calif., June 10
Bright Peak Therapeutics Announces $107 Million Series B Financing and Expanded Board of Directors | Comunicados | Edición USA efe.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from efe.com Daily Mail and Mail on Sunday newspapers.
Published: May 04, 2021
SAN DIEGO (BUSINESS WIRE) Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced that Christine Siu, a life sciences industry leader with more than 20 years of experience in corporate development, strategy and financial roles, has joined the company’s board of directors.
“Christine has an impressive track record of leading both private and public biotechnology companies through critical value-creating inflection points, and we are excited to welcome her to our board of directors,” said Jeffrey Hatfield, chief executive officer of Vividion. “As Vividion continues to make progress building a company and pipeline aimed at delivering precision therapeutics for cancer and immune disorders, we look forward to leveraging her wealth of experience and unique per